论文部分内容阅读
为探讨尿激酶对肾小球肾炎患者血小板活化及凝集功能的影响 ,用全自动血细胞分析仪测定患者治疗前后外周血小板计数 (PC)、体积 (MPV)、分布宽度 (PDW ) ,用ELISA法测定血中纤维蛋白原降解产物(FDP) ,用流式细胞学方法测定患者治疗前后血小板表面颗粒膜蛋白 (GMP 140 )和纤维蛋白原受体 (GPⅡb Ⅲa)表达水平。结果显示 ,10 2例肾炎患者尿激酶疗程结束后PC减少 ,MPV增大 ,差异有显著性意义 (P <0 0 1,PDW加大 ,超过正常值 ;治疗后血小板GMP 140表达水平显著高于治疗前及正常对照组 (P <0 0 1) ,与血中FDP无相关性 ;治疗后血小板GPⅡb Ⅲa表达水平显著低于治疗前及正常对照组 (P <0 0 1) ,与血中FDP呈显著负相关 (P <0 0 5 )。结果提示 ,尿激酶可使血小板活化功能增强 ,血小板破坏增多 ,计数减少 ;使血小板凝集功能减弱 ,有助于减少血小板 纤维蛋白微栓子的形成
To investigate the effect of urokinase on platelet activation and agglutination in patients with glomerulonephritis, peripheral platelet count (PC), volume (MPV) and distribution width (PDW) before and after treatment were measured by automatic hematology analyzer. Serum fibrinogen degradation products (FDP) were measured by flow cytometry before and after treatment on platelet surface membrane protein (GMP 140) and fibrinogen receptor (GP Ⅱ b Ⅲ a) expression levels. The results showed that 10 2 nephritis patients after the reduction of urokinase PC, MPV increased, the difference was significant (P <0.01, PDW increased, exceeding the normal value; after treatment, the expression of platelet GMP 140 was significantly higher than Pretreatment and normal control group (P <0.01), and blood FDP no correlation; after treatment platelet GP Ⅱ b Ⅲ a expression was significantly lower than before treatment and normal control group (P <0.01), and blood FDP (P <0 05) .The results suggest that urokinase can enhance the function of platelet activation, increased platelet destruction, reduced count; platelet aggregation decreased, help to reduce the formation of platelet fibrin micro-emboli